Ponatinib (AP24534) is a potent, ATP-competitive multi-kinase (BCR-ABL, FGFR, PDGFR) inhibitor. It affects PI3K/AKT, MAPK/ERK, and STAT signaling pathways by binding to the kinase ATP-binding site, effectively inhibiting tumor cell proliferation and inducing apoptosis.
Ponatinib (AP24534) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Ponatinib (AP24534) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.